Abstract: Provided is a method for preventing, ameliorating, or treating degenerative diseases caused by cellular senescence, preferably osteoarthritis or atherosclerosis, comprising a specific peptide as an active ingredient, where the peptide remarkably inhibits the interaction of p53 and FOXO4 (Forkhead box protein O4), thereby inhibiting the expression of a cellular senescence regulator.

Abstract: The present invention provides a cosmetic composition for inhibiting or improving seborrhea and a pharmaceutical composition for preventing, improving or treating seborrhea, each composition comprising a specific peptide as an active ingredient. The peptide remarkably decreases the interaction between p53 and MDM2 and thus remarkably increases the interaction between p53 and RNA Polymerase II (POLII), thereby being able to induce expressions of the cytokines that cause apoptosis of sebocytes.

Abstract: Disclosed are peptides and a cosmetics composition using the same peptides. The peptides inhibit the activity of an androgen receptor (AR), whereby the peptides may be used to alleviate androgen-related diseases or disorders such as prostate cancer, skin diseases, and alopecia.

Abstract: Disclosed is a peptide and a cosmetic composition using the same. The peptide inhibits the activity of an aryl hydrocarbon receptor (AhR), whereby the peptide may be used to alleviate skin troubles caused by fine dust.

Abstract: Provided is a peptide fragment derived from secreted frizzled protein 5 (Sfrp5), i.e., a peptide fragment selected from the group consisting of the peptides as set forth in SEQ ID NOs: 1 to 9 and a cosmetic composition for skin-whitening and/or inhibiting skin pigmentation comprising the same as an active ingredient. The peptide fragment inhibits melanin formation in melanocytes, thereby having an inhibitory activity against skin pigmentation. Further provided is a reagent for researching or analyzing the inhibition of Wnt signaling pathways comprising the peptide fragment.

Abstract: The present invention relates to an insulin-A-chain-derived peptide fragment and a pharmaceutical composition for the prevention or treatment of diabetes or diabetic wounds, containing the same as an active ingredient. The peptide of the present invention induces endocytosis through an insulin receptor and exhibits activity of enhancing glucose uptake into cells by translocating a glucose transporter to a cell membrane, and of increasing cell migration and proliferation. Therefore, the peptide of the present invention can be efficiently applied to the prevention or treatment of diabetes or diabetic wounds.

Abstract: Provided is a peptide fragment derived from secreted frizzled protein 5 (Sfrp5), i.e., a peptide fragment selected from the group consisting of the peptides as set forth in SEQ ID NOs: 1 to 9 and a cosmetic composition for skin-whitening and/or inhibiting skin pigmentation comprising the same as an active ingredient. The peptide fragment inhibits melanin formation in melanocytes, thereby having an inhibitory activity against skin pigmentation. Further provided is a reagent for researching or analyzing the inhibition of Wnt signaling pathways comprising the peptide fragment.

Abstract: Provided is a peptide fragment derived from secreted frizzled protein 5 (Sfrp5), i.e., a peptide fragment selected from the group consisting of the peptides as set forth in SEQ ID NOs: 1 to 9 and a cosmetic composition for skin-whitening and/or inhibiting skin pigmentation comprising the same as an active ingredient. The peptide fragment inhibits melanin formation in melanocytes, thereby having an inhibitory activity against skin pigmentation. Further provided is a reagent for researching or analyzing the inhibition of Wnt signaling pathways comprising the peptide fragment.

Abstract: Provided is a pharmaceutical or cosmetic composition comprising adiponectin-derived peptide fragments, i.e., the peptides of SEQ ID NOs: 1 to 6 as an active ingredient. The peptides facilitate skin regeneration and moisturization, inhibit skin wrinkle, and have inhibitory activities against allergy and inflammation as well as metastasis of cancer cells.

Abstract: Provided is a peptide fragment derived from secreted frizzled protein 5 (Sfrp5), i.e., a peptide fragment selected from the group consisting of the peptides as set forth in SEQ ID NOs: 1 to 9 and a cosmetic composition for skin-whitening and/or inhibiting skin pigmentation comprising the same as an active ingredient. The peptide fragment inhibits melanin formation in melanocytes, thereby having an inhibitory activity against skin pigmentation. Further provided is a reagent for researching or analyzing the inhibition of Wnt signaling pathways comprising the peptide fragment.

Abstract: Provided are small peptide fragments derived from microphthalmia-associated transcription factor (MITF) and a method for preventing or treating melanoma using the same as an active ingredient. Further provided is a method for skin-whitening and/or for inhibiting skin pigmentation, using the peptide fragments as an active ingredient.

Abstract: Provided are small peptide fragments derived from the NF-?B p65 subunit and a pharmaceutical or cosmetic composition comprising the same. The peptides have a NF-?B inhibitory activity, through controlling the transcription-activation of NF-?B. The peptides inhibit the expressions of pro-inflammatory mediators, which are induced by NF-?B, and also inhibit the transmigration of leukocytes, thereby exhibiting an anti-inflammatory activity. Especially, the peptides have excellent inhibitory activities against dermatitis and skin aging. And also, the peptides inhibit base membrane invasion of cancer cells, thereby exhibiting an inhibitory activity against the growth and/or metastasis of cancer cells.

Abstract: Provided is a pharmaceutical or cosmetic composition comprising adiponectin-derived peptide fragments, i.e., the peptides of SEQ ID NOs: 1 to 6 as an active ingredient. The peptides facilitate skin regeneration and moisturization, inhibit skin wrinkle, and have inhibitory activities against allergy and inflammation as well as metastasis of cancer cells.

Abstract: The present invention provides small peptide fragments derived from microphthalmia-associated transcription factor (MITF) and a pharmaceutical composition for preventing or treating melanoma comprising the same as an active ingredient. And also, the present invention provides a cosmetic composition for skin-whitening and/or for inhibiting skin pigmentation, comprising the peptide fragments as an active ingredient.

Abstract: The present invention provides small peptide fragments derived from the NF-?B p65 subunit and a pharmaceutical or cosmetic composition comprising the same. The peptides have a NF-?B inhibitory activity, through controlling the transcription-activation of NF-?B. The peptides inhibit the expressions of pro-inflammatory mediators, which are induced by NF-?B, and also inhibit the transmigration of leukocytes, thereby exhibiting an anti-inflammatory activity. Especially, the peptides have excellent inhibitory activities against dermatitis and skin aging. And also, the peptides inhibit base membrane invasion of cancer cells, thereby exhibiting an inhibitory activity against the growth and/or metastasis of cancer cells.

Abstract: The present invention relates to a polypeptide derived from a highly conserved region (HCR) I-III of an extracellular region of a CD99 and CD99 family such as CD99L2 and PBDX(or XG), which are a kind of transmembrane protein, or a fused protein thereof. The polypeptide or the fused protein thereof has an activating function of inhibiting the extravasation of white blood cells, or inhibiting the growth and/or metastasis of cancer cells. The present invention also provides a polynucleotide coding the polypeptide, a vector including same, and a transformant transformed by the vector. In addition, the present invention provides a pharmaceutical composition including the polypeptide or the fused protein thereof for preventing or treating inflammatory diseases. Further, the present invention provides a is pharmaceutical composition including the polypeptide or the fused protein thereof inhibiting the growth and/or metastasis of cancer cells, i.e., a pharmaceutical composition for preventing or treating cancer.

Abstract: The present invention relates to a polypeptide derived from a highly conserved region (HCR) I-III of an extracellular region of a CD99 and CD99 family such as CD99L2 and PBDX (or XG), which are a kind of transmembrane protein, or a fused protein thereof. The polypeptide or the fused protein thereof has an activating function of inhibiting the extravasation of white blood cells, or inhibiting the growth and/or metastasis of cancer cells. The present invention also provides a polynucleotide coding the polypeptide, a vector including same, and a transformant transformed by the vector. In addition, the present invention provides a pharmaceutical composition including the polypeptide or the fused protein thereof for preventing or treating inflammatory diseases. Further, the present invention provides a pharmaceutical composition including the polypeptide or the fused protein thereof inhibiting the growth and/or metastasis of cancer cells, i.e., a pharmaceutical composition for preventing or treating cancer.

Abstract: Described is a polypeptide inhibiting the transmigration of leukocytes or the growth and/or metastasis of cancer cells, a fusion protein thereof, a polynucleotide encoding the polypeptide, a vector including the polynucleotide, and a transformant transformed with the vector. Described is also a pharmaceutical composition for the prevention or treatment of inflammatory diseases, or the inhibition of the growth and/or metastasis of cancer cells including the polypeptide or a fusion protein thereof.

Abstract: The present invention provides a polypeptide inhibiting the transmigration of leukocytes or the growth and/or metastasis of cancer cells, or a fusion protein thereof. The present invention also provides a polynucleotide encoding the polypeptide, a vector including the polynucleotide, and a transformant transformed with the vector. The present invention also provides a pharmaceutical composition for the prevention or treatment of inflammatory diseases including the polypeptide or a fusion protein thereof. The present invention also provides a pharmaceutical composition for inhibiting the growth and/or metastasis of cancer cells including the polypeptide or a fusion protein thereof.

Abstract: The present invention provides a polypeptide or its fusion protein derived from a paired immunoglobulin-like receptor ? or ? (PILR? or PILR?), one of the transmembrane proteins, which inhibits the transmigration of leukocytes or the growth and/or metastasis of cancer cells. The present invention also provides a polynucleotide encoding the polypeptide or its fusion protein, a vector including the polynucleotide, and a transformant transformed with the vector. The present invention also provides a pharmaceutical composition for the prevention or treatment of inflammatory diseases including the polypeptide or a fusion protein thereof. The present invention also provides a pharmaceutical composition for inhibiting the growth and/or metastasis of cancer cells including the polypeptide or a fusion protein thereof.